Drug Metabolism Reviews最新文献

{"title":"Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy.","authors":"Parisa Mohammadi,&nbsp;Reza Yarani,&nbsp;Azam Rahimpour,&nbsp;Fatemeh Ranjbarnejad,&nbsp;Joana Mendes Lopes de Melo,&nbsp;Kamran Mansouri","doi":"10.1080/03602532.2022.2116033","DOIUrl":"https://doi.org/10.1080/03602532.2022.2116033","url":null,"abstract":"<p><p>Anti-angiogenic therapy is a practical approach to managing diseases with increased angiogenesis, such as cancer, maculopathies, and retinopathies. Considering the fundamental gaps in the knowledge of the vital pathways involved in angiogenesis and its inhibition and the insufficient efficiency of existing angiogenesis inhibitors, there is an increasing focus on the emergence of new therapeutic strategies aimed at inhibiting pathological angiogenesis. Angiogenesis is forming a new vascular network from existing vessels; endothelial cells (ECs), vascular lining cells, are the main actors of angiogenesis in physiological or pathological conditions. Switching from a quiescent state to a highly migratory and proliferative state during new vessel formation called \"angiogenic switch\" is driven by a \"metabolic switch\" in ECs, angiogenic growth factors, and other signals. As the characteristics of ECs change by altering the surrounding environment, they appear to have a different metabolism in a tumor microenvironment (TME). Therefore, pathological angiogenesis can be inhibited by targeting metabolic pathways. In the current review, we aim to discuss the EC metabolic pathways under normal and TME conditions to verify the suitability of targeting them with novel therapies.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 4","pages":"386-400"},"PeriodicalIF":5.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10714297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioactivation and reactivity research advances - 2021 year in review.","authors":"Klarissa D Jackson,&nbsp;Upendra A Argikar,&nbsp;Sungjoon Cho,&nbsp;Rachel D Crouch,&nbsp;James P Driscoll,&nbsp;Carley J S Heck,&nbsp;Lloyd King,&nbsp;Hlaing Holly Maw,&nbsp;Grover P Miller,&nbsp;Herana Kamal Seneviratne,&nbsp;Shuai Wang,&nbsp;Cong Wei,&nbsp;Donglu Zhang,&nbsp;S Cyrus Khojasteh","doi":"10.1080/03602532.2022.2097254","DOIUrl":"https://doi.org/10.1080/03602532.2022.2097254","url":null,"abstract":"<p><p>This year's review on bioactivation and reactivity began as a part of the annual review on biotransformation and bioactivation led by Cyrus Khojasteh (see references). Increased contributions from experts in the field led to the development of a stand alone edition for the first time this year focused specifically on bioactivation and reactivity. Our objective for this review is to highlight and share articles which we deem influential and significant regarding the development of covalent inhibitors, mechanisms of reactive metabolite formation, enzyme inactivation, and drug safety. Based on the selected articles, we created two sections: (1) reactivity and enzyme inactivation, and (2) bioactivation mechanisms and safety (Table 1). Several biotransformation experts have contributed to this effort from academic and industry settings.[Table: see text].</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 3","pages":"246-281"},"PeriodicalIF":5.9,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/64/nihms-1898966.PMC10282953.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9756543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetics in drug disposition & drug therapy: symposium report of the 24^th North American meeting of the International Society for the Study of Xenobiotics (ISSX).","authors":"Benjamin J Maldonato,&nbsp;Ana G Vergara,&nbsp;Jaydeep Yadav,&nbsp;Sarah M Glass,&nbsp;Erickson M Paragas,&nbsp;Dongying Li,&nbsp;Philip Lazarus,&nbsp;Joseph L McClay,&nbsp;Baitang Ning,&nbsp;Ann K Daly,&nbsp;Laura E Russell","doi":"10.1080/03602532.2022.2101662","DOIUrl":"https://doi.org/10.1080/03602532.2022.2101662","url":null,"abstract":"<p><p>The 24th North American International Society for the Study of Xenobiotics (ISSX) meeting, held virtually from September 13 to 17, 2021, embraced the theme of \"Broadening Our Horizons.\" This reinforces a key mission of ISSX: striving to share innovative science related to drug discovery and development. Session speakers and the ISSX New Investigators Group, which supports the scientific and professional development of student and early career ISSX members, elected to highlight the scientific content presented during the captivating session titled, \"Epigenetics in Drug Disposition & Drug Therapy.\" The impact genetic variation has on drug response is well established; however, this session underscored the importance of investigating the role of epigenetics in drug disposition and drug discovery. Session speakers, Drs. Ning, McClay, and Lazarus, detailed mechanisms by which epigenetic players including long non-coding RNA (lncRNAs), microRNA (miRNAs), DNA methylation, and histone acetylation can alter the expression of genes involved in pharmacokinetics, pharmacodynamics, and toxicity. Dr. Ning detailed current knowledge about miRNAs and lncRNAs and the mechanisms by which they can affect the expression of drug metabolizing enzymes (DMEs) and nuclear receptors. Dr. Lazarus discussed the potential role of miRNAs on UDP-glucuronosyltransferase (UGT) expression and activity. Dr. McClay provided evidence that aging alters methylation and acetylation of DMEs in the liver, affecting gene expression and activity. These topics, compiled by the symposium organizers, presenters, and the ISSX New Investigators Group, are herein discussed, along with exciting future perspectives for epigenetics in drug disposition and drug discovery research.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 3","pages":"318-330"},"PeriodicalIF":5.9,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970013/pdf/nihms-1865806.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10417662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel insights in drug transporter sciences: the year 2021 in review.","authors":"Paresh P Chothe,&nbsp;Pallabi Mitra,&nbsp;Masanori Nakakariya,&nbsp;Diane Ramsden,&nbsp;Charles J Rotter,&nbsp;Philip Sandoval,&nbsp;Kimio Tohyama","doi":"10.1080/03602532.2022.2094944","DOIUrl":"https://doi.org/10.1080/03602532.2022.2094944","url":null,"abstract":"<p><p>On behalf of the team I am pleased to present the second annual 'novel insights into drug transporter sciences review' focused on peer-reviewed articles that were published in the year 2021. In compiling the articles for inclusion, preprints available in 2021 but officially published in 2022 were considered to be in scope. To support this review the contributing authors independently selected one or two articles that were thought to be impactful and of interest to the broader research community. A similar approach as published last year was adopted whereby key observations, methods and analysis of each paper is concisely summarized in the synopsis followed by a commentary highlighting the impact of the paper in understanding drug transporters' role in drug disposition. As the goal of this review is not to provide a comprehensive overview of each paper but rather highlight important findings that are well supported by the data, the reader is encouraged to consult the original articles for additional information. Further, and keeping in line with the goals of this review, it should be noted that all authors actively contributed by writing synopsis and commentary for individual papers and no attempt was made to standardize language or writing styles. In this way, the review article is reflective of not only the diversity of the articles but also that of the contributors. I extend my thanks to the authors for their continued support and also welcome Diane Ramsden and Pallabi Mitra as contributing authors for this issue (Table 1).[Table: see text].</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"299-317"},"PeriodicalIF":5.9,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biotransformation novel advances - 2021 year in review.","authors":"S Cyrus Khojasteh,&nbsp;Upendra A Argikar,&nbsp;Sungjoon Cho,&nbsp;Rachel Crouch,&nbsp;Carley J S Heck,&nbsp;Kevin M Johnson,&nbsp;Amit S Kalgutkar,&nbsp;Lloyd King,&nbsp;Hlaing Holly Maw,&nbsp;Herana Kamal Seneviratne,&nbsp;Shuai Wang,&nbsp;Cong Wei,&nbsp;Donglu Zhang,&nbsp;Klarissa D Jackson","doi":"10.1080/03602532.2022.2097253","DOIUrl":"https://doi.org/10.1080/03602532.2022.2097253","url":null,"abstract":"<p><p>Biotransformation field is constantly evolving with new molecular structures and discoveries of metabolic pathways that impact efficacy and safety. Recent review by Kramlinger et al. (2022) nicely captures the future (and the past) of highly impactful science of biotransformation (see the first article). Based on the selected articles, this review was categorized into three sections: (1) new modalities biotransformation, (2) drug discovery biotransformation, and (3) drug development biotransformation (Table 1).</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 3","pages":"207-245"},"PeriodicalIF":5.9,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/e1/nihms-1898969.PMC10249656.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9597439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mass spectrometry based protein biomarkers and drug target discovery and clinical diagnosis in Age-Related progressing neurodegenerative diseases.","authors":"Ishita Agrawal,&nbsp;Pallavi Tripathi,&nbsp;Shyamasri Biswas","doi":"10.1080/03602532.2022.2029475","DOIUrl":"https://doi.org/10.1080/03602532.2022.2029475","url":null,"abstract":"<p><p>Neurodegenerative diseases correspond to overly complex health disorders that are driven by intersecting pathophysiology that are often trapped in vicious cycles of degeneration and cognitive decline. The usual diagnostic route of these diseases is based on postmortem examination that involves identifying pathology that is specific to the disease in the brain. However, in such cases, accurate diagnosis of the specific disease is limited because clinical disease presentations are often complex that do not easily allow to discriminate patient's cognitive, behavioral, and functional impairment profiles. Additionally, an early identification and therapeutic intervention of these diseases is pivotal to slow the progression of neurodegeneration and extend healthy life span. Mass spectrometry-based techniques have proven to be hugely promising in biological sample analysis and discovery of biomarkers including protein and peptide biomarkers for potential drug target discovery. Recent studies on these biomarkers have demonstrated their potential for applications in early diagnostics and identifying therapeutic targets to battle against neurodegenerative diseases. In this review, we have presented principles of mass spectrometry (MS) and the associated workflows in analyzing and imaging biological samples for discovery of biomarkers. We have especially focused on age-related progressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD) and the related MS-based biomarker developments for these diseases. Finally, we present a future perspective discussing the potential research directions ahead.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 1","pages":"22-36"},"PeriodicalIF":5.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39917390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell-Biomaterial constructs for wound healing and skin regeneration.","authors":"Ingrid Safina,&nbsp;Luke T Childress,&nbsp;Srinivas R Myneni,&nbsp;Kieng Bao Vang,&nbsp;Alexandru S Biris","doi":"10.1080/03602532.2021.2025387","DOIUrl":"https://doi.org/10.1080/03602532.2021.2025387","url":null,"abstract":"<p><p>Over the years, conventional skin grafts, such as full-thickness, split-thickness, and pre-sterilized grafts from human or animal sources, have been at the forefront of skin wound care. However, these conventional grafts are associated with major challenges, including supply shortage, rejection by the immune system, and disease transmission following transplantation. Due to recent progress in nanotechnology and material sciences, advanced artificial skin grafts-based on the fundamental concepts of tissue engineering-are quickly evolving for wound healing and regeneration applications, mainly because they can be uniquely tailored to meet the requirements of specific injuries. Despite tremendous progress in tissue engineering, many challenges and uncertainties still face skin grafts <i>in vivo</i>, such as how to effectively coordinate the interaction between engineered biomaterials and the immune system to prevent graft rejection. Furthermore, in-depth studies on skin regeneration at the molecular level are still not fully understood; as a consequence, the development of novel biomaterial-based systems that interact with the skin at the core level has also been slow. This review will discuss (1) the biological aspects of wound healing and skin regeneration, (2) important characteristics and functions of biomaterials for skin regeneration applications, and (3) synthesis and applications of common biomaterials for skin regeneration. Finally, the current challenges and future directions of biomaterial-based skin regeneration will be addressed.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 1","pages":"63-94"},"PeriodicalIF":5.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39896309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Through a glass, darkly? HepaRG and HepG2 cells as models of human phase I drug metabolism.","authors":"Lesley A Stanley, C Roland Wolf","doi":"10.1080/03602532.2022.2039688","DOIUrl":"10.1080/03602532.2022.2039688","url":null,"abstract":"<p><p>The pharmacokinetic and safety assessment of drug candidates is becoming increasingly dependent upon <i>in vitro</i> models of hepatic metabolism and toxicity. Predominant among these is the HepG2 cell line, although HepaRG is becoming increasingly popular because of its perceived closer resemblance to human hepatocytes. We review the functionality of these cell lines in terms of Phase I protein expression, basal cytochrome P450-dependent activity, and utility in P450 induction studies. Our analysis indicates that HepG2 cells are severely compromised: proteomic studies show that they express few key proteins in common with hepatocytes and they lack drug-metabolizing capacity. Differentiated HepaRGs are more hepatocyte-like than HepG2s, but they also have limitations, and it is difficult to assess their utility because of the enormous variability in data reported, possibly arising from the complex differentiation protocols required to obtain hepatocyte-like cells. This is exacerbated by the use of DMSO in the induction protocol, together with proprietary supplements whose composition is a commercial secret. We conclude that, while currently available data on the utility of HepaRG generates a confusing picture, this line does have potential utility in drug metabolism studies. However, to allow studies to be compared directly a standardized, reproducible differentiation protocol is essential and the cell line's functionality in terms of known mechanisms of P450 regulation must be demonstrated. We, therefore, support the development of regulatory guidelines for the use of HepaRGs in induction studies as a first step in generating a database of consistent, reliable data.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 1","pages":"46-62"},"PeriodicalIF":3.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39941805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between <i>UGT1A1</i> gene & various diseases and prevention strategies.","authors":"Dan Liu,&nbsp;Qi Yu,&nbsp;Qing Ning,&nbsp;Zhongqiu Liu,&nbsp;Jie Song","doi":"10.1080/03602532.2021.2001493","DOIUrl":"https://doi.org/10.1080/03602532.2021.2001493","url":null,"abstract":"<p><p>UDP-glucuronyltransferase 1A1 (UGT1A1) is a member of the Phase II metabolic enzyme family and the only enzyme that can metabolize detoxified bilirubin. Inactivation and very low activity of UGT1A1 in the liver can be fatal or lead to lifelong Gilbert's syndrome (GS) and Crigler-Najjar syndrome (CN). To date, more than one hundred UGT1A1 polymorphisms have been discovered. Although most UGT1A1 polymorphisms are not fatal, which diseases might be associated with low activity UGT1A1 or UGT1A1 polymorphisms? This scientific topic has been studied for more than a hundred years, there are still many uncertainties. Herein, this article will summarize all the possibilities of <i>UGT1A1</i> gene-related diseases, including GS and CN, neurological disease, hepatobiliary disease, metabolic difficulties, gallstone, cardiovascular disease, Crohn's disease (CD) obesity, diabetes, myelosuppression, leukemia, tumorigenesis, etc., and provide guidance for researchers to conduct in-depth study on <i>UGT1A1</i> gene-related diseases. In addition, this article not only summarizes the prevention strategies of <i>UGT1A1</i> gene-related diseases, but also puts forward some insights for sharing.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 1","pages":"1-21"},"PeriodicalIF":5.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39757878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>GSTM1</i> and <i>GSTT1</i> polymorphisms in healthy volunteers - a worldwide systematic review.","authors":"Giovana Nakanishi,&nbsp;Laísa S Bertagnolli,&nbsp;Murilo Pita-Oliveira,&nbsp;Mariana M Scudeler,&nbsp;Sabrina Torres-Loureiro,&nbsp;Thaís Almeida-Dantas,&nbsp;Maria Laura C Alves,&nbsp;Heithor S Cirino,&nbsp;Fernanda Rodrigues-Soares","doi":"10.1080/03602532.2022.2036996","DOIUrl":"10.1080/03602532.2022.2036996","url":null,"abstract":"<p><p>The <i>GSTM1</i> and <i>GSTT1</i> genes encode homonymous enzymes, which are responsible for the detoxification of several substances potentially harmful to the human body, such as air pollution, drugs, pesticides, and tobacco. However, some individuals may present a complete deletion of these genes and, consequently, an enzyme deficiency leading to an inadequate metabolism and, therefore, a higher susceptibility to some clinical conditions. Interethnic variations have also been described for both genes, making necessary the study of the deletion frequencies of <i>GSTM1</i> and <i>GSTT1</i> in different populations around the world. So, the aim of this study was to enable the synthesis and discussion of the main population differences of <i>GSTM1</i> and <i>GSTT1</i> polymorphisms in healthy volunteers. Searches were performed in the PubMed database, including 533 articles and 178,566 individuals in the analyses. We found an overrepresentation of European individuals and studies, and an underrepresentation of non-European ethnicities. Moreover, there are significant frequency differences among distinct ethnic groups: East Asians present the highest frequencies worldwide for <i>GSTM1</i> and <i>GSTT1</i> deletions, which could suggest higher disorders risk for this population; in contrast, Sub-Saharan Africans presented the lowest frequency of <i>GSTM1</i> worldwide, corroborating evolution inferences performed previously for other genes codifying metabolism enzymes. Also, admixture is a relevant component when analyzing frequency values for both genes, but further studies focusing on this subject are warranted.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"54 1","pages":"37-45"},"PeriodicalIF":5.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39877606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}